Nisa Investment Advisors LLC Buys 2,803 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Nisa Investment Advisors LLC grew its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 52.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,112 shares of the biopharmaceutical company’s stock after acquiring an additional 2,803 shares during the quarter. Nisa Investment Advisors LLC’s holdings in TG Therapeutics were worth $244,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. The Manufacturers Life Insurance Company raised its position in TG Therapeutics by 3.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 80,664 shares of the biopharmaceutical company’s stock valued at $1,435,000 after purchasing an additional 2,871 shares during the last quarter. Algert Global LLC raised its holdings in shares of TG Therapeutics by 193.8% in the second quarter. Algert Global LLC now owns 147,218 shares of the biopharmaceutical company’s stock valued at $2,619,000 after buying an additional 97,118 shares during the last quarter. Creative Planning raised its holdings in shares of TG Therapeutics by 34.7% in the second quarter. Creative Planning now owns 46,839 shares of the biopharmaceutical company’s stock valued at $833,000 after buying an additional 12,076 shares during the last quarter. Quarry LP lifted its position in TG Therapeutics by 9.1% during the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 503 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in TG Therapeutics by 181.9% in the 3rd quarter. SG Americas Securities LLC now owns 23,614 shares of the biopharmaceutical company’s stock valued at $552,000 after buying an additional 15,238 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX opened at $33.37 on Thursday. The stock has a market capitalization of $5.19 billion, a price-to-earnings ratio of -333.67 and a beta of 2.24. The firm has a fifty day simple moving average of $31.72 and a 200 day simple moving average of $26.41. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12 month low of $12.84 and a 12 month high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business’s revenue was down 49.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.73 EPS. Research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TGTX. TD Cowen began coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company. The Goldman Sachs Group upped their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

Insider Activity

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the transaction, the chief financial officer now directly owns 670,632 shares of the company’s stock, valued at $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,358 shares of company stock valued at $781,497. 10.50% of the stock is owned by insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.